GC Pharma snipes JW Pharmaceutical. Hemlibra, a hemophilia treatment that JW Pharmaceutical is introducing and selling in Korea, became the target. GC Pharma distributed a press release on the 21st. It is a press release titled, 'The report rate of abnormal blood clots in Hemlibra was 2.8 times higher than Factor XIII.'

This press release was written based on the information presented at the American Society for Bleeding Disorders Conference. Based on the U.S. Food and Drug Administration (FDA) adverse event reporting system, JW Pharma's Hemlibra and GC Pharma's XIII formulation were compared. As a result, Hemlibra's thrombotic adverse event reporting rate was 4.07%, which was 2.83 times higher than Fac